目的 调查2018—2019年复旦大学附属妇产科医院紫杉醇类药品的使用情况，为妇科恶性肿瘤患者治疗合理用药提供相关数据资料。方法 回顾性分析复旦大学附属妇产科医院2018—2019年医嘱中含紫杉醇类药品的使用情况，对药品的使用量、销售金额、患者年龄、临床诊断、药品的用法用量、用药疗程等进行整理与分析。结果 共收集含紫杉醇类药品医嘱12 398条，涉及7种紫杉醇类药品，两年年总使用量68 170瓶，用量前3名分别是国产多西他赛注射液22 633瓶，构成比为33.20%；国产注射用紫杉醇脂质体20 273瓶，构成比为29.74%，国产紫杉醇注射液13 430瓶，构成比为19.70%。销售金额前3名的分别是国产注射用紫杉醇脂质体1 625.59万元，构成比为46.93%，进口紫杉醇注射液587.99万元，构成比为16.98%，进口注射用紫杉醇（白蛋白结合型）577.70万元，构成比为16.68%。使用紫杉醇类药品最多的年龄段是59～60岁，构成比为34.88%。临床诊断数的前3位分别宫颈癌908例，构成比为53.57%，卵巢癌697例，构成比为41.12%，乳腺癌564例，构成比为33.27%。紫杉醇脂质体和紫杉醇注射液的最常使用量为210 mg，进口多西他赛注射液的最常使用量为100 mg，国产多西他赛注射液的最常使用量为120 mg，进口注射用紫杉醇（白蛋白结合型）的最常使用量为150 mg。紫杉醇类药品疗程数分布1～39次，其中疗程小于10次的人数构成比为96.74%。结论 2018—2019年复旦大学附属妇产科医院紫杉醇类药品的使用合理，但还需要更多地关注不良反应发生等相关问题，确保患者安全、有效、经济用药，并进一步结合临床真实数据的分析，规范紫杉醇类药品领域评价原则，建立较为完整的评估系统。

Objective To analyze the clinical use of paclitaxel drugs in Obstetrics and Gynecology Hospital Affiliated to Fudan University from 2018 to 2019, and to provide reference for the rational treatment of patients with gynecological tumors. Methods The uses of paclitaxel drugs in Obstetrics and Gynecology Hospital Affiliated to Fudan University from 2018 to 2019 were analyzed retrospectively, including usages, sales, ages of patients, clinical diagnoses, dosage and course of treatment. Results A total of 12 398 medical orders containing paclitaxel drugs were collected, involving 7 kinds of paclitaxel drugs. The total amount used in the two years was 68 170 bottles. The drugs with top three dosages were Domestic Docetaxel Injection, 22 633 bottles, accounting for 33.20%, Domestic Paclitaxel Liposome for injection, 20 273 bottles, accounting for 29.74%, and Domestic Paclitaxel Injection, 13 430 bottles, accounting for 19.70%. The drugs with top three sales amount were Domestic Paclitaxel Liposome for injection with an amount of RMB 16.25 million, accounting for 46.93%, Imported Paclitaxel Injection with RMB 5.88 million, accounting for 16.98%, and Imported Paclitaxel injection (albumin-binding type) with RMB 5.78 million, accounting for 16.68%. The age group with the most paclitaxel drugs using was people aged 59 — 60 years, accounting for 34.88%. The top three clinical diagnoses were cervical cancer with 908 patients, accounting for 53.57%, ovarian cancer with 697 patients, accounting for 41.12%, and breast cancer with 564 patients, accounting for 33.27%. The most commonly dosage of Paclitaxel Liposome and Paclitaxel Injection was 210 mg, while 100 mg for Imported Docetaxel Injection, 120 mg for Domestic Docetaxel Injection, and 150 mg for Imported Paclitaxel Injection (albumin-binding type). The treatment courses of paclitaxel drugs are distributed from 1 to 39 times, and 96.74% of the patients have less than 10 treatment courses. Conclusion From 2018 to 2019, the use of paclitaxel drugs in Obstetrics and Gynecology Hospital Affiliated to Fudan University is reasonable, but some issues such as adverse reactions need to be concerned. The safety, effectiveness, and economical efficiency for patients should be ensured. Furthermore, the clinical real data should be analyzed and a complete evaluation system for clinical use of paclitaxel drugs should be established.

R969.3

上海市临床药学重点专科建设项目（AB83110002017005）